Tyrosine Protein Kinase Receptor UFO Pipeline Review, H2 2019
Summary
Tyrosine Protein Kinase Receptor UFO AXL Oncogene or AXL or EC 2.7.10.1 Tyrosineprotein kinase receptor UFO is an enzyme encoded by the AXL gene. It plays a role in various processes such as endothelial cell survival during acidification by preventing apoptosis, optimal cytokine signaling during human natural killer cell development, hepatic regeneration, gonadotropinreleasing hormone neuron survival and migration, platelet activation, or regulation of thrombotic responses. It plays also an important role in inhibition of Tolllike receptors TLRsmediated innate immune response.
Tyrosine Protein Kinase Receptor UFO AXL Oncogene or AXL or EC 2.7.10.1 pipeline Target constitutes close to 32 molecules. Out of which approximately 30 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in PreRegistration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 3, 5, 7, 10 and 4 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Oncology, Cardiovascular, Gastrointestinal, Non Malignant Disorders and Respiratory which include indications NonSmall Cell Lung Cancer, Acute Myelocytic Leukemia AML, Acute Myeloblastic Leukemia, Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Solid Tumor, Gastric Cancer, Breast Cancer, Melanoma, Metastatic Colorectal Cancer, Ovarian Cancer, Metastatic Melanoma, TripleNegative Breast Cancer TNBC, Adenocarcinoma Of The Gastroesophageal Junction, Bladder Cancer, Cervical Cancer, Chronic Lymphocytic Leukemia CLL, Chronic Myelocytic Leukemia CML, Chronic Myeloid Leukemia, Colorectal Cancer, Endometrial Cancer, Epithelial Ovarian Cancer, Esophageal Cancer, Ewing Sarcoma, Gastroesophageal GE Junction Carcinomas, Head And Neck Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Hepatocellular Carcinoma, Metastatic Hormone Refractory Castration Resistant, AndrogenIndependent Prostate Cancer, Metastatic Renal Cell Carcinoma, Metastatic Uveal Melanoma, Myelodysplastic Syndrome, Osteosarcoma, Pancreatic Cancer, Renal Cell Carcinoma, Rhabdomyosarcoma, Soft Tissue Sarcoma, Thyroid Cancer, Wilms' Tumor Nephroblastoma, Adenocarcinoma, Adrenocortical Carcinoma Adrenal Cortex Cancer, Bile Duct Cancer Cholangiocarcinoma, Bone Metastasis, Carcinoid Tumor, Colon Cancer, Fallopian Tube Cancer, Follicular Thyroid Cancer, Gallbladder Cancer, Gastrointestinal Stromal Tumor GIST, Glioblastoma Multiforme GBM, HighGrade Glioma, Idiopathic Pulmonary Fibrosis, Kidney Cancer Renal Cell Cancer, Leiomyosarcoma, Liposarcoma, Liver Cancer, Lung Adenocarcinoma, Malignant Mesothelioma, Mantle Cell Lymphoma, Merkel Cell Carcinoma, Metastatic Adenocarcinoma of The Pancreas, Metastatic Biliary Tract Cancer, Metastatic Breast Cancer, Metastatic Hepatocellular Carcinoma HCC, Metastatic Ovarian Cancer, Metastatic Transitional Urothelial Tract Cancer, Neuroendocrine Gastroenteropancreatic Tumors GEPNET, Neuroendocrine Tumors, NonAlcoholic Steatohepatitis NASH, NonHodgkin Lymphoma, NonRhabdomyosarcoma, NonSmall Cell Lung Carcinoma, Oral Cavity Mouth Cancer, Osteolytic Bone Metastasis, Pancreatic Ductal Adenocarcinoma, Papillary Renal Cell Carcinoma, Papillary Thyroid Cancer, Paraganglioma Glomus Jugulare Tumor, Penile Cancer, Peritoneal Cancer, Pheochromocytoma, Plexiform Neurofibroma, Prostate Cancer, Rectal Cancer, Recurrent Head And Neck Cancer Squamous Cell Carcinoma, Refractory Multiple Myeloma, Relapsed Multiple Myeloma, Salivary Gland Cancer, Squamous Cell Carcinoma, TCell Acute Lymphocytic Leukemia TCell Acute Lymphoblastic Leukaemia, Thrombosis, Thymoma Thymic Epithelial Tumor, Transitional Cell Cancer Urothelial Cell Cancer, Transitional Cell Carcinoma Urothelial Cell Carcinoma, Ureter Cancer, Urethral Cancer and Uterine Cancer.
The latest report Tyrosine Protein Kinase Receptor UFO Pipeline Review, H2 2019, outlays comprehensive information on the Tyrosine Protein Kinase Receptor UFO AXL Oncogene or AXL or EC 2.7.10.1 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action MoA, route of administration RoA and molecule type. It also reviews key players involved in Tyrosine Protein Kinase Receptor UFO AXL Oncogene or AXL or EC 2.7.10.1 targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industryspecific third party sources.
Scope
The report provides a snapshot of the global therapeutic landscape for Tyrosine Protein Kinase Receptor UFO AXL Oncogene or AXL or EC 2.7.10.1
The report reviews Tyrosine Protein Kinase Receptor UFO AXL Oncogene or AXL or EC 2.7.10.1 targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industryspecific sources
The report covers pipeline products based on various stages of development ranging from preregistration till discovery and undisclosed stages
The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, RD brief, licensing and collaboration details other developmental activities
The report reviews key players involved in Tyrosine Protein Kinase Receptor UFO AXL Oncogene or AXL or EC 2.7.10.1 targeted therapeutics and enlists all their major and minor projects
The report assesses Tyrosine Protein Kinase Receptor UFO AXL Oncogene or AXL or EC 2.7.10.1 targeted therapeutics based on mechanism of action MoA, route of administration RoA and molecule type
The report summarizes all the dormant and discontinued pipeline projects
The report reviews latest news and deals related to Tyrosine Protein Kinase Receptor UFO AXL Oncogene or AXL or EC 2.7.10.1 targeted therapeutics
Reasons to buy
Gain strategically significant competitor information, analysis, and insights to formulate effective RD strategies
Identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage
Identify and understand the targeted therapy areas and indications for Tyrosine Protein Kinase Receptor UFO AXL Oncogene or AXL or EC 2.7.10.1
Identify the use of drugs for target identification and drug repurposing
Identify potential new clients or partners in the target demographic
Develop strategic initiatives by understanding the focus areas of leading companies
Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
Devise corrective measures for pipeline projects by understanding Tyrosine Protein Kinase Receptor UFO AXL Oncogene or AXL or EC 2.7.10.1 development landscape
Develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope